Cognitive and Alzheimer's Disease Biomarker Effects of Oral Nicotinamide Riboside (NR) Supplementation in Older Adults with Subjective Cognitive Decline and Mild Cognitive Impairment

Objective

To test the safety and efficacy of oral NR supplementation on cognition and Alzheimer’s disease (AD) blood biomarkers in older adults with subjective cognitive decline and mild cognitive impairment (MCI).

Study Design

Randomized, double-blind, placebo-controlled, crossover study in 46 older adults with subjective cognitive decline and MCI

Dose

1000 mg

Duration

8 weeks

Key Outcomes

  • NR supplementation had no impact on cognition.

  • NR resulted in a 7% reduction in plasma pTau217 concentrations, a biomarker for AD, while placebo resulted in an 18% increase.

Clinical, Neurological HealthANAD Staff